Aromatase inhibitors versus tamoxifen in early breast cancer. patient-level meta-analysis of the randomised trials. Lancet Lond Engl. 2015;386(10001):1341–52.

Article  Google Scholar 

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol [Internet]. 2023 Sep 6 [cited 2023 Sep 7];0(0)

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.

Article  CAS  PubMed  Google Scholar 

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5(1):1–8.

Article  CAS  Google Scholar 

Finn RS, Rugo HS, Dieras VC, Harbeck N, Im SA, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (pal+let) versus placebo plus letrozole (PbO+let) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/her2−ABC): Analyses from PALOMA-2. J Clin Oncol. 2022, 40: 003

Mayer EL, Demichele AM, Pfeiler G, Barry W, Metzger O, Rastogi P, et al. PALLAS: PALbociclib CoLlaborative adjuvant study: a randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. Annals Oncol. 2017;28:v66. https://doi.org/10.1093/annonc/mdx362.064.

Article  Google Scholar 

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Stroyakovskiy D, Yardley DA, Huang C-S, Fasching PA, Crown J, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(17_suppl):LBA500–LBA500. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500.

Article  Google Scholar 

Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol [Internet]. 2023 Dec 13 [cited 2023 Dec 26];0(0)

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(12):1475–95.

Article  CAS  Google Scholar 

Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435–46.

CAS  PubMed  Google Scholar 

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006;103(20):7795–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 2002;21(25):4000–8.

Article  CAS  PubMed  Google Scholar 

Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol. 2004;24(19):8681–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pegram M, Jackisch C, Johnston SRD. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer. 2023;9(1):45.

Article  PubMed  PubMed Central  Google Scholar 

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women With Her2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(1):79–89.

Article  CAS  Google Scholar 

Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-Line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase ii trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(28):2826–35.

Article  CAS  Google Scholar 

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29(3):255–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19(2):249–56.

Article  CAS  PubMed  Google Scholar 

Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763–75.

Article  CAS  PubMed  Google Scholar 

Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, et al. Palbociclib and Trastuzumab in HER2-positive advanced breast cancer: results from the Phase II SOLTI-1303 PATRICIA trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(22):5820–9.

Article  CAS  Google Scholar 

Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P, et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Ann Oncol. 2018 Oct 1;29: viii121

Viganò L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, et al. Modulation of the estrogen/erbB2 Receptors cross-talk by cdk4/6 inhibition triggers sustained senescence in Estrogen Receptor– and ErbB2-positive breast cancer. Clin Cancer Res. 2022;28(10):2167–79.

Article  PubMed  PubMed Central  Google Scholar 

Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):398–405.

Article  CAS  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated her2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. J Clin Oncol. 2021 May 20;39(15_suppl):1022–1022

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–35.

Article  CAS  PubMed  Google Scholar 

Enhertu | European Medicines Agency [Internet]. [cited 2023 Dec 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu

Center for Drug Evaluation and Research. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. FDA [Internet]. 2022 Aug 5 [cited 2023 May 22]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer

Andre F, Hamilton EP, Loi S, Im S-A, Sohn J, Tseng L-M, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). J Clin Oncol. 2022;40(16_suppl):3025–3025. https://doi.org/10.1200/JCO.2022.40.16_suppl.3025.

Article  Google Scholar 

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142–53.

Article  CAS  PubMed  Google Scholar 

Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, et al. Prognostic and biologic significance of ERBB2-Low expression in early-stage breast cancer. JAMA Oncol. 2022;8(8):1177–83.

PubMed  PubMed Central  Google Scholar 

Tolaney Sara M, Garrett-Mayer Elizabeth, White Julia, Blinder Victoria S, Foster Jared C, Amiri-Kordestani L, et al. Updated standardized definitions for efficacy end points (STEEP) in Adjuvant breast cancer clinical trials: STEEP Version 2.0. J Clin Oncol. 2021;39(24):2720–31. https://doi.org/10.1200/JCO.20.03613.

Article  PubMed  PubMed Central  Google Scholar 

Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon